Stock Overview

10X Genomics Inc (TXG)

NASDAQ · Healthcare · Health Information Services

10X Genomics Inc is a Healthcare company with a market capitalization of $6.56B.

Market Cap
$6.56B
Forward P/E
827.4
Price/Sales
10.6
Price/Book
8.0
EV/EBITDA
147.4
Beta
2.04
EPS (TTM)
$-0.59
Profit Margin
-3.5%
ROE
-9.4%
Short % of Float
13.8%
Days to Cover
5.3
52W High
$58.57
52W Low
$11.34

5-Year Price History

Latest Annual Financials · FY ending December 31, 2025

Revenue
$642.82M
Gross Profit
$443.88M
Operating Income
-$110.89M
Net Income
-$43.54M
Free Cash Flow
$130.12M
Total Debt
$10.98M
Cash & Equivalents
$473.97M
Shareholder Equity
$796.33M

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q1 2026May 7, 2026$0.07$-0.06+216.7%
Q4 2025February 12, 2026$0.07$-0.04+275.0%
Q3 2025November 6, 2025$-0.02$-0.07+71.4%
Q2 2025August 7, 2025$0.28$-0.35+180.0%
Q1 2025May 8, 2025$-0.10$-0.29+65.5%
Q4 2024February 12, 2025$-0.14$-0.11-27.3%

Short Interest

FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.

SettlementShares Short% of Shares OutDays to CoverChange
July 15, 202616,252,51912.67%5.3-0.5%
June 30, 202616,339,59612.74%4.2-26.1%
June 15, 202622,103,16017.23%6.8+34.0%
May 29, 202616,492,73712.86%5.5-25.6%
May 15, 202622,153,76617.27%7.9+36.4%
April 30, 202616,248,29412.79%6.1-1.4%
April 15, 202616,474,24812.96%7.1+2.8%
March 31, 202616,020,77712.61%6.5+1.3%

Other Health Information Services Stocks

Frequently Asked Questions

What is 10X Genomics Inc's market cap?

As of August 13, 2026, 10X Genomics Inc (TXG) has a market capitalization of $6.56B.

Does 10X Genomics Inc pay a dividend?

10X Genomics Inc does not currently pay a dividend.

What sector is TXG in?

10X Genomics Inc is in the Healthcare sector, specifically the Health Information Services industry.

What is 10X Genomics Inc's short interest?

As of the July 15, 2026 FINRA settlement, 16,252,519 TXG shares were sold short, or 12.67% of shares outstanding. Days to cover: 5.3. FINRA publishes short interest twice a month, about nine business days after each settlement date.

What was 10X Genomics Inc's revenue?

In its latest reported fiscal year (ending December 31, 2025), 10X Genomics Inc reported revenue of $642.82M and net income of -$43.54M.

Ask your own questions about TXG

Try mrmarket.ai free

Data as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.